José
Palacios Calvo
Profesor/a Titular Universidad
![Foto de José](/img/nophoto.png)
![Foto de Instituto Valenciano de Oncologia](/img/noimage_org.png)
Instituto Valenciano de Oncologia
Valencia, EspañaPublications en collaboration avec des chercheurs de Instituto Valenciano de Oncologia (10)
2023
-
The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)
International journal of molecular sciences, Vol. 24, Núm. 13
2022
-
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
Journal of Personalized Medicine, Vol. 12, Núm. 11
2020
-
Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications
European Journal of Cancer, Supplement, Vol. 15, pp. 1-15
2018
-
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)
Clinical and Translational Oncology
-
Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
-
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285
2017
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
2013
-
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814